Taiwan Develops Innovative Alternative to Horseshoe Crab Blood for Crucial Bacterial Testing

A groundbreaking new method promises to protect endangered horseshoe crab populations while ensuring drug safety.

In a significant advancement for both medical testing and conservation efforts, Taiwan has successfully developed a novel testing reagent. This new development offers a viable alternative to the use of horseshoe crab blood, a substance traditionally employed for detecting bacteria in veterinary drugs.

While the new testing method is reported to be more costly than the traditional approach utilizing horseshoe crab blood, its implementation is expected to significantly improve the survival rates of these unique marine creatures. This initiative stems from growing concerns over the impact of horseshoe crab blood harvesting on the species' long-term viability.

Horseshoe crabs are renowned for their distinctive blue blood, which possesses high medical value. This blood is a critical component in the production of reagents essential for vaccine and drug development. These reagents are highly sensitive and react rapidly, causing clotting or color changes when exposed to injectable solutions contaminated with harmful bacteria, thereby signaling a potential health risk.

However, the process of collecting horseshoe crab blood has placed considerable strain on their populations. These creatures take a substantial 10 to 15 years to reach maturity. Disturbingly, studies indicate that approximately 30% of horseshoe crabs do not survive the blood extraction process. Furthermore, the blood collection can negatively impact the reproductive capabilities of female crabs, raising serious concerns about the species' future and leading to their classification as endangered in various regions.

The application of these reagents, derived from horseshoe crab blood, began in clinical medicine, environmental monitoring, and food safety in 2004. After processing, the blood commands a high market value, with reports suggesting it can be worth approximately NT$500,000 (US$15,625) per liter. To ensure a consistent domestic supply, a dedicated horseshoe crab breeding facility was established in Taiwan.

While traditional Chinese medicine texts have historically attributed benefits to the horseshoe crab, such as supporting kidney function and enhancing vitality, its consumption can present significant health hazards. A notable incident in 2022 involved an individual in Pingtung who suffered acute liver failure after consuming raw horseshoe crab blood. Their condition only stabilized following intensive treatment with multiple antibiotics.

Medical professionals emphasize the critical importance of proper sterilization and disinfection for any animal blood intended for medicinal use. This precautionary measure is vital to mitigate the risks associated with parasites and bacterial infections, ensuring the safety of both veterinary and human applications.